Ten lumbar disk levels in nine patients were examined by computed tomography (CT) before and 6 weeks after chymopapain chemonucleolysis of herniated nucleus pulposus (HNP). Patient selection for chemonucleolysis was partly based on CT scans demonstrating morphologic HNP criteria favoring a successful treatment outcome. Posttreatment CT scans disclosed a measurable HNP size decrease of 1-3 mm at nine of 10 levels studied as well as an increase in HNP attenuation at many levels. CT findings correlated closely with objective clinical parameters used to assess treatment outcomes.
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Over the past decade chemonucleolysis therapy in selected cases of lumbosacral herniated nucleus pulposus (HNP) has gained increasing acceptance as an alternative to surgical diskectomy, laminectomy , and fusion [1] [2] [3] [4] [5] [6] [7] [8] . Several recent largescale clinical evaluations have reported 70%-74% improvement rates in symptoms and signs after chemonucleolysis [9] [10] [11] [12] [13] compared with a 41 % improvement rate after placebo intradiskal injections [14] . Furthermore, a recent prospective study reported a 91 % clinical improvement rate for chymopapain-treated patients who had failed to improve after recent intradiskal placebo injections [14] .
Clinical improvement after chymopapain chemonucleolysis appears to be from marked HNP size reduction , which results in decreased mass effect on adjacent nerve roots [15] . To date, clinical evaluations of chemonucleolysis outcomes have relied primarily on changes in symptomatic complaints and physical findings. However, a recently published text on diagnostic imaging of spinal column disorders includes three brief reports of computed tomographic (CT) finding s in postchemonucleolysis patients [16] [17] [18] . Insofar as CT served as the primary imaging method guiding selection of chemonucleolysis patients at our institution, we undertook to evaluate chemonucleolysis outcomes by CT in patients treated by this means at our hospital.
Subjects and Methods
The first nine patients treated with chemonucleolysis at our institution between September 1983 and May 1984 were included in our prospective study. Patients were scanned 1 week before and 6 weeks after treatment. Ten chemonucleolysis-treated lumbosacral disk levels were evaluated before and after chemonucleolysis .
Patients were selected for chemonucleolysis therapy by E. H. S. and H. O. after meeting each of seven criteria: (1) persistence of unremitting sciatica symptoms for at least 12 months without treatment or for at least 3 months during a trial of conservative therapy ; (2) ipsilateral extensor hallucis longus weakness for patients with L4-L5 HNP ; (3) diminution of ipsilateral Achilles tendon reflex for patients with L5-S1 HNP ; (4) positive straight-leg-rai sing test; (5) positive electromyographic findings ; (6) CT findings of HNP without distally migrated disk fragments ; and (7) patient preference for chemonucleolysis therapy over the alternative of either continued conservative management or surgical diskectomy and fusion .
From September to December 1983, scanning was periormed on a GE 8800 CT rr scanner using 120 kVp , 400 mA, 3 msec pulse width , and 9.6 sec scan time . Prospective Soft Tissue Note.-HNP = herniated nucleus pulposus . . Rescanning at 12 weeks postchymopapain disclosed minimal interval progression in HNP size decrease (from -2 to -3 mm) and relative attenuation increase (from + 10 to + 14 H) since 6 week postchymopapain scan.
ReView Reconstruction algorithm was used with target magnification to a 20 cm field of view using 35 or 42 cm norms and 1.7 photographic magnification of axial images at soft-tissue settings. From January to May 1984, scanning was performed on a GE 9800 B CT /T scanner using 140 kV , 170 rnA , 3 sec scan time , Standard reconstruction algorithm with a 12.8 cm field of view and 512 x 512 display matrix. All axial scans were obtained using 5 mm collimation , 3 mm consecutive intervals (2 mm through narrow interspaces), and gantry angulation approximating inters paces. All axial scans were photographed at soft-ti ssue settings (width , 150-250 H; variable levels) using a oneon-one format. All axial scans were also rephotographed at bone settings (width , 1200-1500 H; level , 350-450 H) without magnification using a four on one format.
All GE 8800 scans requiring comparison with GE 9800 B scans were enlarged to a 512 x 512 display matrix before comparison . Scans clearly disclosing HNPs were photographed three times: unblinked , blinked for HNP, and blinked for thecal sac using a blink window of 25 H. Careful matching of anatomic landmarks was performed to select the most similar axial images depicting HNPs on pre-and posttreatment scans.
Perfect matching of all anatomic landmarks on pre-and posttreatment scans was not possible due to the 6 week interval between these scans as well as the interspace narrowing that frequently occurred after chymopapain injections . Optimal matching was performed by making comparisons of all adjacent scans obtained at 2-3 mm consecutive intervals through the disk space of interest on preand posttreatment scans . The single pair of matched pre-and posttreatment axial scans affording clearest HNP visualization was selected for HNP size and attenuation measurements in all cases . These scans usually disclosed the largest midsagittal HNP dimension demonstrable on any axial image .
Caliper measurements of maximal HNP size (to the nearest millimeter) were performed in the parasagittal plane by two observers (B. M. B. and G. D.) without knowledge of clinical outcome of chemonucleolytic treatment . The difference between pre-and posttreatment maximal HNP size measurements was then determined for each level studied .
Pre-and posttreatment HNP attenuations were then interactively measured using blink-level adjustments on the same axial images selected for HNP size measurements . Each image was first examined while blinking the majority of HNP pixels, then reexamined wh ile blinking the majority of thecal sac pixels. Absolute attenuation va lues (in Hounsfield units) were then recorded for HNP (AHNp) and for thecal sac (Ad based on blink-mode measurements . As an internal control for variable beam-hardening artifacts generated by tissues surrounding the HNP , thecal sac attenuation values were used to calculate a relative HNP attenuation (RAHNP) in accordance with the formula: RA HNP = A HNP -A rs . Posttreatment change in relative HNP attenuation (t.RAHNP) was then calculated :
Clinical evaluations of posttreatment outcomes were performed 6 weeks after chymopapain by E. H. S. and H. O. who had selected chemonucleolysis patients and performed the chymopapain injections . Clinical outcomes were rated without knowledge of CT findings on a 1-5 scale (least to most) using parameters of reliability of patient history , improvement in presenting symptomatic complaints , and improvement in presenting abnormal physical findings. Improvement was rated from 1 (no improvement) to 5 (marked improvement). Patients were also assessed in terms of resumption of prior employment when applicable.
Results
Pre-and postchemonucleolysis CT measurements of HNP size and density are presented in table 1. Nine of 10 levels showed measura NP ' e decreases of 1-3 mm after c pain injection figs. 1 and 2), although these size c w re not always obvious on initial inspection of hardcopy scans. These measurable changes represented a 12.5%-43.5°
. itial HNP size 6 weeks after _ tre~nt. A fJdnher slight HNP dimiOlltlon..(from 2 to 3 mm was also noted 6-12 weeks posttrea~n a single case scanned twice after chemonucleolysis (case 6) . Many of the levels disclosing HNP reductions also showed.~erspace ~ narrowing on lateral scout views as well as interval a ear----a~entral interspace gas collections:.3bout one-half 0 levels also showed at least a 10 H increase in relative HNP ~sity after treatment ( fig . 3 ) .
Clinical evaluation data arep1esented in table 2. Seven of nine patients disclosed moderate to marked improvement in presenting symptoms and signs. Two patients reported new onset of diffuse back pain without radicular symptoms or signs during the first month after treatment. Both of these patients disclosed marked improvement of presenting symptoms and physical findings at rescanning . One patient (case 10) reported no symptomatic relief after chemonucleolysis and disclosed neither an improvement in physical findings nor size decrease in a moderately large HNP with possible migrated disk fragment. Another patient (case 1) denied any A B symptomatic relief despite unequivocal improvement in presenting signs as well as HNP size decreases on CT scans through each of two treated disks. Concordance between -i rovement in presenting abnormalities on physical examination and HNP size eases on--cT scan~a<' neteG-ifl-
Discussion
Chymopapain is a proteolytic enzyme that lyses voluminous chondromucoprotein gel complexes in HNP fragments . Both the proteoglycans (glycosamino glycogen) and the intercellular matrix comprising chondromucoproteins appear to be hydrolysed by chymopapain , [19 , 20] . Collagen fibers that , in addition to chondromucoproteins , constitute a major structural component of the nucleus pulposus , are unaffected by chymopapain [20] . Chondromucoprotein gel complexes (due A B Note.-Improvement was rated from 1 (no improvement) to 5 (marked Improvement). NA concerns patients receiving disability compensation for an extended period before chemonucleolysis.
to their high water-binding capacity) have a much greater volume than collagen fibers and hence serve as the major determinant of HNP fragment size [21] . This chymopapaininduced hydrolysis of HNP chondromucoproteins acts to reduce HNP fragment size and extrinsic mass effect on adjacent nerve roots .
Chymopapain binds strongly and immediately upon contact with chondromucoprotein complexes after intradiskal injection [20 , 22] . Thus , hydrolytic activity remain s closely localized to the site of injection . Furthermore, chymopapain undergoes early rapid inactivation by Circulating proteolytic enzyme inhibitors in plasma (alpha 2 macroglobulins), and delayed antibody formation to the chymopapain enzyme also occurs [15] . The resulting spatial and temporal constraints on the extent of chymopapain action significantly influences HNP morphology criteria for chemonucleolysis patient selection.
Several widely accepted patient HNP morphology criteria favor successful chemonucleolysis outcome: (1) relatively small HNP size , (2) localization of HNP at posterior disk margin, and (3) absence of distally migrated HNP fragments .
Patients selected for chemonucleolysis treatment in the current study were readily assessed in terms of these HNP morphology criteria by CT. CT appeared more capable than myelography of diagnosing distally migrated HNP fragments, which excluded patients as chemonucleolysis candidates at our institution . As a result , CT served an essential function in cherryonucleolysis patient selection .
/Nine of 10 posttreatment CT scans in our patients disclosed ! rlleasurable decreases in HNP sizes at 6 weeks after chy--m0papain injections. Absolute HNP size decreases of 1-3 mm at times were not obvious on cursory visual inspection and required careful measurement of HNP size on pre-and posttreatment scans closely matched for anatomic location. An earlier study [23J demonstrated that decreases in vertebral body interspaces occurred primarily within 2 months postchemonucleolysis , although minimal additional decreases were observed up to 6 months. Although a minimal incremental HNP size decrease 6-12 weeks posttreatment was noted in a single instance in our study, it appeared that CT was capable of routinely demonstrating HNP size changes at 6 weeks after chemonucleolysis. ~ Many disk levels evaluated in our study disclosed a measurable change in HNP attenuation after chemonucleolysis . This increase in posttreatment HNP density probably reflects desiccation of HNP material after chymopapain injection. A _recent magnetic resonance imaging study of lumbar disk herniation [24J suggested that desiccation of HNP material may also be the mechanism responsible for an observed decrease in the normal high-intensity nucleus pulposus signal -af:ter chemonucleolysis . ~jecti\le physical findings agreed closely with CT findings of decreased HNP size in the current study. Most patients showed improvement in initial symptoms and signs at 1i. weeks after chymopapain treat~t. Most employed patients were able to return to work after treatment. One patient, rated as an unreliable historian with a long-term unemployment record , denied any symptomatic relief after treatment despite unequivocal improvement in presenting physical findings and a decrease in HNP size on CT. Mild central canal stenosis was present on this patient's scans and may have contributed to persistence of his symptoms. A review of this case suggested that this patient should probably not be regarded as a treatment failure due to improvement in both physical findings and decrease in HNP size on CT scans. The significance of two instances of initial diffuse back pain posttreatment is unclear, although both of these patients disclosed improvement in both presenting symptoms and signs , as well as CT findings by 6 weeks after chymo-,PaPain injection .
Our preliminary experience suggests that CT is capable of detecting HNP size decreases at 6 weeks after chemonucleolysis and thus may contribute to the objective evaluation of -Gu1come for thi. §.. treatment. Additional experience with preand postchemonucleolysis CT should help define the role of CT in patients who report persistent posttreatment symptomatology and might be uniformly designated as treatment failures in the absence of objective treatment outcome criteria.
